在WGCNA和整合性网络分析中,CHRNA5和CTLA4被确定为抗血管肉瘤的潜在治疗点
Trishla Bhatnagar1, Madiha Haider1, Mohd Yasir Khan1
1Department of Biotechnology, Jamia Millia Islamia, New Delhi, India 110025.
Cancer treatment and research communications
|January 20, 2025
概括
这项研究确定了血管瘤中的关键分子特征,揭示了八个持续过度表达的基因. CHRNA5和CTLA4显示出针对这种侵袭性软组织肉瘤的向治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 血管瘤是源自内皮细胞的侵袭性软组织瘤.
- 关于它们的分子病理生理学的研究有限,特别是转录组分析.
研究的目的:
- 为了确定不同来源的血管瘤中共享的分子特征和基因模块.
- 通过基因表达分析发现潜在的治疗点.
主要方法:
- 公共数据集的转录数据分析.
- 重量基因同表达网络分析 (WGCNA) 用于识别基因模块.
- 最大集群集中性 (MCC) 和未聚类网络分析以识别枢纽基因.
- 基因表达特征交互分析 (GEPIA) 用于跨癌症表达特征分析.
主要成果:
- WGCNA确定了五个重要的模块,其中最丰富的与血管生成和细胞结节调节有关.
- 在所有血管肉瘤样本中发现了8个持续过度表达的基因.
- 与其他癌症相比,CHRNA5和CTLA4在血管瘤中被发现完全过度表达.
- 对于这些候选基因,发现了显著的药物蛋白相互作用.
结论:
- 共享的分子特征和基因模块与血管瘤有关.
- CHRNA5和CTLA4是有希望的,针对血管肉瘤的治疗点.
- 对这些基因的进一步调查可能会导致血管肉瘤的新型治疗策略.
更多相关视频
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
681
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Canonical Wnt Signaling Pathway
8.7K
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.7K
Non-Canonical Wnt Signaling Pathways
7.2K
Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.2K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Tumor Immunotherapy
468
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
468
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
